Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab

Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil activation, and blocks IgE binding to CD23 on B cells...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Biol Chem
Asıl Yazarlar: Davies, Anna M., Allan, Elizabeth G., Keeble, Anthony H., Delgado, Jean, Cossins, Benjamin P., Mitropoulou, Alkistis N., Pang, Marie O. Y., Ceska, Tom, Beavil, Andrew J., Craggs, Graham, Westwood, Marta, Henry, Alistair J., McDonnell, James M., Sutton, Brian J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Biochemistry and Molecular Biology 2017
Konular:
Immunology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5473249/
https://ncbi.nlm.nih.gov/pubmed/28438838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M117.776476
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller